Acadia's Nuplazid Hits A Review Roadblock, But Not A CRL (For Now)

Deficiencies identified by the US FDA could delay the approval of pimavanserin for hallucinations associated with dementia-related psychosis, but Acadia did not have details for investors.

Wooden roadblock in nature
The road to approval for a Nuplazid sNDA is uncertain • Source: Shutterstock

The outlook for the expansion of ACADIA Pharmaceuticals Inc.'s Nuplazid (pimavanserin) to treat hallucinations and delusions associated with dementia-related psychosis is uncertain after the company received an update from the US Food and Drug Administration. The company warned there could be a delay in approval of a supplemental new drug application (sNDA) for Nuplazid, but management did not have any details so the message was a confusing one for investors to absorb.

After markets closed on 8 March, Acadia provided an update on the status of the review, stating that the FDA...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category